Targets › MGMT
9 programs from 8 companies in 10 trials: 4 Phase 2, 3 Phase 3, 3 Phase 1; Oncology; next expected readout Dec 2026.
Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated. (UniProt, P16455)
Open in Phaseline: the race on MGMT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Centre Oscar Lambret | Temozolomide (TMZ) Alkylating agent; DNA methylating agent that induces O6-methylguanine lesions | MGMT | Phase 3 | Glioblastoma | Jun 2027 |
| Alliance for Clinical Trials in Oncology | Concomitant temozolomide (TMZ) Alkylating agent; DNA methylating chemotherapy | MGMT | Phase 3 | Brain and Central Nervous System Tumors | Oct 2029 |
| Leland Metheny | O6-benzylguanine Purine analog that selectively and irreversibly inactivates O6-alkylguanine DNA-alkyltrans | MGMT | Phase 2 | Glioblastoma Multiforme | Mar 2027 |
| Leland Metheny | P140K-MGMT Ex vivo cultured CD34+ hematopoietic stem cells transduced with P140K MGMT gene to confer | MGMT | Phase 2 | Glioblastoma Multiforme | Mar 2027 |
| Sunnybrook Health Sciences Centre | Dose escalation + Reduced Margin Adaptive Radiotherapy on MR-Linac with concurre Hypofractionated radiotherapy with simultaneous integrated boost (SIB) delivered via MR-gu | MGMT | Phase 2 | Glioblastoma Multiforme, Adult | Dec 2027 |
| AHS Cancer Control Alberta | Temozolomide DNA alkylating agent; induces DNA damage leading to cell death | MGMT | Phase 2 | Glioblastoma Multiforme | Jun 2032 |
| John Flickinger | Temozolomide Alkylating agent; methylates DNA at N-7 guanine and N-3 adenine positions | MGMT | Phase 1 | Glioblastoma | Dec 2026 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Temozolomide Alkylating agent; DNA methylating agent with activity in MGMT-methylated tumors | MGMT | Phase 1 | Metastatic Colorectal Cancer | Jan 2027 |
| Neonc Technologies | NEO212 Covalent conjugate of temozolomide and perillyl alcohol (POH-TMZ) | MGMT | Phase 1 | Diffuse Astrocytoma, IDH-Mutant | Feb 2027 |
Glioblastoma Multiforme (3) Brain and Central Nervous System Tumors (2) Glioblastoma (2) Glioblastoma Multiforme, Adult (1) Diffuse Astrocytoma, IDH-Mutant (1) Metastatic Colorectal Cancer (1)
small molecule (4), mixed (4)
Leland Metheny (2) Alliance for Clinical Trials in Oncology (1) Sunnybrook Health Sciences Centre (1) AHS Cancer Control Alberta (1) Neonc Technologies (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) John Flickinger (1) Centre Oscar Lambret (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.